My second question is about patents for pharmaceutical products.
The technical summary of the final negotiated outcomes of the Canada-EU CETA stipulates that Canada's federal government is prepared to address incremental cost impacts if concessions to the EU in this area have a financial impact on provincial and territorial governments.
How would incremental cost impacts be assessed, and by whom?